Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.46 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227699 | 0.84 | P2RX7 (0.62) | P2RX7NPC1RAB9AALDH1A1HTT | |
| SCHEMBL5227112 | 0.82 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL5229533 | 0.82 | P2RX7 (0.50) | P2RX7LMNARAB9AMEN1ALDH1A1 | |
| SCHEMBL5227908 | 0.79 | P2RX7 (0.58) | P2RX7LMNANPC1RAB9AMEN1 | |
| SCHEMBL10254128 | 0.78 | P2RX7 (0.41) | P2RX7MAPTALDH1A1L3MBTL1 | |
| SCHEMBL508731 | 0.78 | P2RX7 (0.41) | P2RX7MAPTTHRB | |
| SCHEMBL3403485 | 0.77 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL5225028 | 0.75 | KCNH2 (0.51) | P2RX7HTTL3MBTL1 | |
| SCHEMBL5227612 | 0.75 | CYP3A4 (0.48) | LMNAMAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL5228191 | 0.74 | P2RX7 (0.41) | P2RX7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | P2RX7 2065/4885TDP1 68/4885ERCC1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.